Neyrodoz in the treatment of secondary premature ejaculation in patients with chronic prostatitis

Abstract

Premature ejaculation (PE) is the type of sexual dysfunction, which is characterized by constant or nearly constant uncontrolled ejaculation before vaginal penentration or within minutes of the start of sexual intercourse, that causing a feeling of sexual dissatisfaction and leading to sexual frustration among the partners. It has been shown that the antimicrobial and antiinflammatory therapy of chronic prostatitis (CP) increases the duration of sexual intercourse and improves the control over the ejaculation. PE in the patients with CP may be an independent sexual disorder that may require a specific correction. Antidepressants are the first line of drugs in the treatment of PE according to the recommendations of the European Association of Urology. However, some patients refuse to intake this medicine. The aim of our study was to evaluate the clinical efficacy and safety of Neyrodoz in the treatment of PE in patients with CP. Materials and methods. The study included 32 patients (mean age 37.5 years) who have had complains on PE after the treatment of CP. All the patients were randomly selected into two groups. 1 st – basic group (n = 15) and 2 nd – control group (n = 17). The first group patients intook Neyrodoz 2 capsules twice a day. The second group got placebo in the same dose during 30 days. Results . The time of intravaginal latency increased from 40,8 ± 9,9 (25–56) to180,1± 41,2 (120–240) seconds in patients of the 1 st group after the therapy. The score of tool-PEDT decreased from 15,8 ± 3,1 (11–20) to 3,9 ± 2,9 (0–8). The visual analogue scale (VAS) symptoms improved from 8,6 ± 1,4 (6–10) to 2,5 ± 2,1 (0–5). The time of intravaginal latency increased from 38,4 ± 10,0 (25–59) to 40,7 ± 7,4 (35–59) seconds in 14 of 17 men in the second group of patients. The score of tool-PEDT decreased from 15,6 ± 2,8 (11–20) to 14,3 ± 2,7 (12–19). The VAS symptoms improved from 8,9 ± 1,3 (6–10) to 8,5 ± 1,7 (6–10). Conclusions. Neyrodoz is an effective and safe medicine to the correction of PE in patients with CP, who did not get an effect after the treatment of CP.